<DOC>
	<DOCNO>NCT00146601</DOCNO>
	<brief_summary>The purpose study test effectiveness safety fulvestrant premenopausal woman advance breast cancer .</brief_summary>
	<brief_title>Fulvestrant Premenopausal Women With Hormone Receptor-Positive Breast Cancer</brief_title>
	<detailed_description>Patients receive injection fulvestrant first day treatment 2 week later 2 week . Then patient receive injection every 4 week . Routine blood test perform time injection give . Patients require complete hot flash diary , record number severity hot flash experience daily basis . After every 12 week treatment , patient ' disease assess x-rays scan . If disease progression , patient continue receive injection every 4 week reassessment every 8 week . Patients continue receive treatment long disease progression serious side effect .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<criteria>Histologically cytologically confirm invasive breast cancer , stage IV disease . Tumors must positive estrogen receptor , progesterone receptor , . Patients must premenopausal . Prior antiestrogen therapy ( without ovarian suppression ) Platelet count &gt; 100,000/mm3 Age old 18 year ECOG performance status 02 Hormonal treatment metastatic disease Pregnant breastfeed woman Postmenopausal Concurrent hormonal therapy chemotherapy Prior fulvestrant therapy More three prior chemotherapy regimens metastatic disease Concurrent , longterm anticoagulation therapy Severe , uncontrolled intercurrent illness History hypersensitivity castor oil</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Fulvestrant</keyword>
	<keyword>Advanced breast cancer</keyword>
	<keyword>Invasive breast cancer</keyword>
	<keyword>Stage IV Breast Cancer</keyword>
	<keyword>Hormone Receptor-Positive Breast Cancer</keyword>
</DOC>